Home » Archive

News

News, Syndication, Xconomy »

Option to Buy: The New Face of Biotech Funding?

Posted by sandiegobiotech February 13th, 2012 .
No Comments

When Cambridge, MA-based Warp Drive Bio launched on January 10, the startup was as notable for its financing structure as it was for its technology—maybe more. That’s because part of the $125 million…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

SD Life Sciences Roundup: Illumina, Applied Proteomics, & Tocagen

Posted by sandiegobiotech February 10th, 2012 .
No Comments

—It wasn’t exactly news when the board at San Diego-based Illumina (NASDAQ: ILMN) said it had rejected the $5.7 billion hostile takeover offer from Swiss drug maker Roche. Now Wall Street’s…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Persistence Pays Off for Synchroneuron Founder

Posted by sandiegobiotech February 9th, 2012 .
No Comments

When Barry Fogel first started developing a new treatment 15 years ago, his main goal was to help his own patients. Fogel, a physician trained in both psychiatry and neurology, saw many patients with…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Ardea Biosciences to Present at Upcoming Investor Conferences

Posted by Mary Canady February 8th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Feb 8, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences in February 2012:

More...

News, Syndication, Xconomy »

OncoSec Medical Advancing Inovio’s Technology Against Cancer

Posted by sandiegobiotech February 8th, 2012 .
No Comments

OncoSec Medical CEO Punit Dhillon tells me the startup he helped establish in San Diego last March is beginning mid-stage safety and efficacy trials of its proprietary technology for enhancing drug…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Life Sciences VC Investing Up in Dollar Value, Down in Deal Volume

Posted by sandiegobiotech February 7th, 2012 .
No Comments

At first glance, a report released last week by PricewaterhouseCoopers and the National Venture Capital Association seems to portend rich times for life sciences startups. Biotech companies raised…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

Applied Proteomics, Co-Founded by Danny Hillis, Gets New CEO, $22.5M

Posted by sandiegobiotech February 7th, 2012 .
No Comments

Applied Proteomics hasn’t exactly been operating in stealth mode since it was founded five years ago. Co-founders David Agus, a cancer specialist at USC, and Danny Hillis, the MIT-trained computer…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid Arthritis

Posted by Mary Canady February 6th, 2012 .
No Comments

SYDNEY, AUSTRALIA and SAN DIEGO, CA–(Marketwire – Feb 6, 2012) – Benitec Biopharma (ASX: BLT) and Medistem (PINKSHEETS: MEDS) announced today the successful treatment of rheumatoid arthritis in preclinical models using Benitec Biopharma’s patented …

More...

Marketwire, News, Syndication »

Ardea Biosciences Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock

Posted by Mary Canady February 6th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – Feb 6, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares sold pursuant to the full exerci…

More...

News, Syndication, Xconomy »

FDA vs. Drug Ads: Cut the Kids and Dogs, Spell Out Side Effects

Posted by sandiegobiotech February 6th, 2012 .
No Comments

If you’ve turned on your TV anytime in the last, oh, decade or so, you’ve no doubt been bombarded by ads imploring you to “ask your doctor” about Drug X. And you’re well familiar with the routine:…

[[Click headline to continue reading.]]

More...